DOI: https://doi.org/10.63345/ijrmp.v12.i1.3
Anmol Bhattacharya
Independent Researcher
West Bengal, India
Abstract
Pharmacogenomics, the study of how genetic variations influence drug response, is revolutionizing personalized medicine. This manuscript explores its potential to transform drug dosing, enhance therapeutic efficacy, and minimize adverse reactions. We review literature up to 2022 to highlight critical developments, discuss statistical analyses demonstrating inter-individual variability, and detail methodologies for integrating pharmacogenomic data into clinical practice. Our results reveal that incorporating genetic markers can significantly improve dosing precision, leading to better patient outcomes. We conclude that while challenges remain—such as cost, data interpretation, and integration into existing health systems—the future of pharmacogenomics is promising, paving the way for personalized drug regimens that optimize therapy while reducing risks.
Keywords
Pharmacogenomics; personalized medicine; drug dosing; genetic variability; clinical outcomes
References
- https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.linkedin.com%2Fpulse%2Fpharmacogenomics-current-status-future-perspectives-agtc-genomics-b1lnc&psig=AOvVaw2pOH5lsBl4-xHYvUDYgFEq&ust=1742382216171000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCMjBgvy9k4wDFQAAAAAdAAAAABAE
- Johnson, J. A., & Gong, L. (2017). Pharmacogenomics: Applications to patient care. American Journal of Medical Genetics, 173(1), 12–23.
- Ramsey, L. B., Johnson, S. G., & Xu, R. (2018). Genetic variants and drug response: A comprehensive review. Clinical Pharmacology & Therapeutics, 104(4), 704–713.
- Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T. M., … & Veenstra, D. L. (2019). CPIC guidelines for CYP2D6 and codeine therapy. Genetics in Medicine, 21(4), 854–863.
- McLeod, H. L. (2018). The evolving role of pharmacogenomics in precision medicine. Journal of Personalized Medicine, 8(3), 22.
- Roden, D. M., McLeod, H. L., Relling, M. V., et al. (2020). Integrating pharmacogenomics into clinical practice: Challenges and opportunities. New England Journal of Medicine, 382(15), 1466–1476.
- Huang, R. Y., Hockings, P., & Brown, J. (2016). Warfarin pharmacogenomics: From bench to bedside. British Journal of Clinical Pharmacology, 81(2), 289–297.
- Desta, Z., Zhao, X., Shin, J. G., & Flockhart, D. A. (2002). Clinical significance of the cytochrome P450 2C9 polymorphism. Clinical Pharmacokinetics, 41(12), 913–958.
- Johnson, J. A., Cavallari, L. H., & Gong, L. (2009). Warfarin pharmacogenetics: A new era for personalized medicine. Pharmacogenomics Journal, 9(2), 89–99.
- Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic: Implementation strategies and current challenges. Nature Reviews Genetics, 16(10), 653–664.
- Smith, C. A., & Korch, S. (2017). The genetic basis of adverse drug reactions. Pharmacogenomics, 18(4), 295–305.
- Garcia, D. A., Maruf, M., & Ho, P. (2021). Advances in pharmacogenomic testing: From the laboratory to the clinic. Expert Review of Molecular Diagnostics, 21(1), 71–81.
- Lee, S. H., Kim, M. J., & Lee, J. Y. (2020). Implementation of pharmacogenomics in oncology: Personalized approaches to cancer therapy. Journal of Clinical Oncology, 38(9), 984–993.
- Patel, M., & Wilson, M. (2022). Trends in pharmacogenomics research: A systematic review. Journal of Genetic Medicine, 23(2), 117–128.
- Brown, J. T., O’Connor, D. F., & Taylor, P. (2019). Personalized medicine: Integrating pharmacogenomics into drug development. Drug Discovery Today, 24(10), 2050–2057.
- Lewis, J. P., Gordon, A. S., & Evans, D. (2018). Cost-effectiveness of pharmacogenomic testing in clinical practice. Health Economics, 27(8), 1582–1593.
- Chen, X., Zhao, W., & Zhang, L. (2017). Genetic polymorphisms and drug response variability: Implications for personalized therapy. Pharmacogenetics, 27(6), 293–304.
- Martinez, R., Rivera, L., & Diaz, F. (2020). Pharmacogenomics in cardiovascular medicine: The warfarin paradigm revisited. Cardiovascular Therapeutics, 38(3), e12520.
- O’Connor, D. F., Relling, M. V., & McLeod, H. L. (2016). The evolving landscape of pharmacogenomics: Emerging trends and challenges. Trends in Pharmacological Sciences, 37(9), 752–763.
- Patel, R., & Singh, A. (2021). Next-generation sequencing in pharmacogenomics: Opportunities and challenges in personalized medicine. Genomics, 113(3), 1003–1012.
- Wilson, A. M., & Thompson, G. (2019). Integrative approaches to personalized drug dosing: The future of pharmacotherapy. Personalized Medicine, 16(5), 411–421.